Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Int J Mol Sci. 2022 Mar 13;23(6):3093. doi: 10.3390/ijms23063093.
Acute kidney injury (AKI) has impacted a heavy burden on global healthcare system with a high morbidity and mortality in both hospitalized and critically ill patients. However, there are still some shortcomings in clinical approaches for the disease to date, appealing for an earlier recognition and specific intervention to improve long-term outcomes. In the past decades, owing to the predictable base-pairing rule and highly modifiable characteristics, nucleic acids have already become significant biomaterials for nanostructure and nanodevice fabrication, which is known as nucleic acid nanotechnology. In particular, its excellent programmability and biocompatibility have further promoted its intersection with medical challenges. Lately, there have been an influx of research connecting nucleic acid nanotechnology with the clinical needs for renal diseases, especially AKI. In this review, we begin with the diagnostics of AKI based on nucleic acid nanotechnology with a highlight on aptamer- and probe-functionalized detection. Then, recently developed nanoscale nucleic acid therapeutics towards AKI will be fully elucidated. Furthermore, the strengths and limitations will be summarized, envisioning a wiser and wider application of nucleic acid nanotechnology in the future of AKI.
急性肾损伤 (AKI) 给全球医疗保健系统带来了沉重负担,住院和重症患者的发病率和死亡率都很高。然而,迄今为止,临床上对这种疾病的治疗方法仍然存在一些不足,需要更早的识别和特定的干预措施来改善长期预后。在过去几十年中,由于碱基配对规则的可预测性和高度可修饰性,核酸已成为纳米结构和纳米器件制造的重要生物材料,这被称为核酸纳米技术。特别是,其出色的可编程性和生物相容性进一步促进了它与医学挑战的交叉。最近,越来越多的研究将核酸纳米技术与肾脏疾病(尤其是 AKI)的临床需求联系起来。在这篇综述中,我们首先介绍了基于核酸纳米技术的 AKI 诊断,重点介绍了适体和探针功能化检测。然后,将全面阐述针对 AKI 的新型纳米尺度核酸治疗方法。此外,还将总结其优缺点,以期在未来的 AKI 中更明智、更广泛地应用核酸纳米技术。